For example, daily oral administration of bovine myelin in patients with relapsing–remitting (RR) MS reduced the frequency of myelin basic protein (MBP)-specific T cells in a phase I trial [33]; however, it did not improve clinical manifestations of MS in a larger phase III trial [34], and there are also some safety concerns regarding hypersensitive reactions [35]. Here, MBP is linked to myeloid sarcoma.